SEARCH

SEARCH BY CITATION

References

  • 1
    Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996; 23: 164176.
  • 2
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988; 8: 11511157.
  • 3
    Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38(Suppl)1: S69S89.
  • 4
    Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 18191827.
  • 5
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-Del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 6
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 16371648.
  • 7
    Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. HEPATOLOGY 1998; 27: 3541.
  • 8
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999; 29: 16901697.
  • 9
    Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. HEPATOLOGY 1999; 30: 870875.
  • 10
    Uríz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 4348.
  • 11
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923930.
  • 12
    Ortega R, Ginès P, Uríz J, Cárdenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002; 36: 941948.
  • 13
    Ginès A, Escorsell A, Ginès P, Salo J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229236.
  • 14
    Papper S. Hepatorenal syndrome. In: EpsteinM, ed. The Kidney in Liver Disease. Amsterdam, The Netherlands: Elsevier Science Publishing Co. Inc., 1983: 87106.
  • 15
    Arroyo V. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. J Hepatol 2002; 36: 315320. Reprinted from Lancet 1956;2:1221-1225.
  • 16
    Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851858.
  • 17
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 9196.
  • 18
    Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 715.
  • 19
    Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. HEPATOLOGY 2004; 39: 764769.
  • 20
    Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB, McDiarmid SV, Merion RM, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl 2004; 10: A6A22.
  • 21
    Freeman RB. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection. Liver Transpl 2004; 10: S2S3.
  • 22
    Salo J, Ginès A, Quer JC, Fernandez-Esparrach G, Guevara M, Ginès P, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996; 25: 916923.
  • 23
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. HEPATOLOGY 1998; 28: 416422.
  • 24
    Ginès P, Uríz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 18391847.
  • 25
    Asbert M, Jiménez W, Gaya J, Ginès P, Arroyo V, Rivera F, et al. Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin. J Hepatol 1992; 15: 179183.
  • 26
    Asbert M, Ginès A, Ginès P, Jiménez W, Claria J, Salo J, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 14851491.
  • 27
    Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983; 13: 271278.
  • 28
    Poggio M, van den Besselaar AM, van der Velde EA, Bertina RM. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 1989; 62: 868874.
  • 29
    Ginès P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. HEPATOLOGY 1998; 28: 851864.
  • 30
    Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease. HEPATOLOGY 2001; 33: 473475.
  • 31
    Everson GT. MELD: the answer or just more questions? Gastroenterology 2003; 124: 251254.
  • 32
    Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl 2003; 9: 1921.
  • 33
    Tome S, Botero RC, Lucey MR. The MELD system and organ allocation policy: lessons after the first year of use in the United States. Gastroenterol Hepatol 2004; 27: 3540.
  • 34
    Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004; 291: 18711874.
  • 35
    Arroyo V, Bosch J, Gaya-Beltran J, Kravetz D, Estrada L, Rivera F, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94: 198201.
  • 36
    Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482487.
  • 37
    Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88: 514519.
  • 38
    Maroto A, Ginès A, Salo J, Claria J, Ginès P, Anibarro L et al. Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. HEPATOLOGY 1994; 20: 839844.
  • 39
    Moreau R. Hepatorenal syndrome: incidence, predictive factors and prognosis. Gastroenterol Clin Biol 1994; 18: 541543.
  • 40
    Fernandez-Esparrach G, Sanchez-Fueyo A, Ginès P, Uríz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 4652.
  • 41
    Vesin P. Late functional renal failure in cirrhosis with ascites: pathophysiology, diagnosis and treatment. In: MartininGA, SherlockS, eds. Aktuelle Probleme der Hepatologie. Stuttgart, Germany: Georg Thieme Verlag, 1962: 5460.
  • 42
    Abasi ZA, Winaver J, Skorecki KL. Control of extracellular fluid volume and the pathophysiology of edema formation. In: BrennerBM, editor. The Kidney. Philadelphia: Saunders, 2004: 777856.
  • 43
    Martin PY, Schrier RW. Pathogenesis of water and sodium retention in cirrhosis. Kidney Int Suppl 1997; 59: S43S49.
  • 44
    Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2004; 40: 5564.
  • 45
    Nicholls KM, Shapiro MD, Groves BS, Schrier RW. Factors determining renal response to water immersion in non-excretor cirrhotic patients. Kidney Int 1986; 30: 417421.
  • 46
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 17741778.
  • 47
    Epstein M, Goligorsky MS. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 1997; 10: 120135.
  • 48
    Warner L, Skorecki KL, Blendis LM, Epstein M. Atrial natriuretic factor and liver disease. HEPATOLOGY 1993; 12: 500513.
  • 49
    Ginès P, Fernandez-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175189.
  • 50
    Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. HEPATOLOGY 2003; 38: 12101218.
  • 51
    Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? HEPATOLOGY 2003; 38: 10891091.
  • 52
    Ginès P, Guevara M, Perez-Villa F. Management of hepatorenal syndrome: another piece of the puzzle. HEPATOLOGY 2004; 40: 1618.
  • 53
    Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988; 319: 10651072.
  • 54
    Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990; 113: 155159.
  • 55
    Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 16581676.